Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology, Inc. entered into an underwriting agreement for an underwritten public offering of 20,000,000 shares of common stock at a public offering price of $1.50 per share, for gross proceeds of approximately $30 million before fees and expenses. The underwriter has a 30-day option to buy up to an additional 3,000,000 shares to cover over-allotments. The deal is issued off MAIA’s effective Form S-3 shelf registration and closed on March 4, 2026. Company officers and directors agreed to a 60-day lock-up on certain sales, and MAIA plans to use net proceeds to fund clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology, Inc. is offering 20,000,000 shares of common stock at a public offering price of
The offering includes a 30-day option for the underwriters to purchase up to 3,000,000 additional shares. The underwriters expect to deliver the shares on or about
MAIA Biotechnology, Inc. is offering shares of its common stock and pre-funded warrants pursuant to a shelf prospectus supplement dated
MAIA Biotechnology filed an 8-K to share a 2026 shareholder letter and press release highlighting progress for its lead cancer drug candidate, ateganosine, in non-small cell lung cancer (NSCLC). The company is running an ongoing Phase 3 full-approval clinical trial, which it describes as having a high probability of technical success for interim and full analyses.
Ateganosine is presented as a first-in-class, telomere-targeting immunotherapy being developed initially as a third-line treatment for NSCLC patients who have failed prior checkpoint inhibitor and chemotherapy regimens. MAIA emphasizes the lack of an established standard of care in this setting, estimating a U.S. population of about 50,000 such patients annually and positioning ateganosine as creating a differentiated revenue opportunity.
The company notes FDA Fast Track designation for ateganosine as third-line NSCLC therapy and references a potential commercial opportunity within a cited $50 billion global immunotherapy market. Management’s letter underscores optimism about the program’s momentum, the broader pipeline, and the long-term potential for ateganosine across multiple cancer indications, while including detailed forward-looking statement cautions.
MAIA Biotechnology, Inc. filed a current report to note that it issued a press release titled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum.” The release, attached as an exhibit, focuses on progress in the company’s Ateganosine cancer treatment program and its planned clinical milestones for 2026.
The report emphasizes that these updates are forward-looking statements and may differ from actual results. MAIA highlights key uncertainties, including the timing, cost and results of preclinical and clinical studies, the ability to advance product candidates through trials and regulatory review, manufacturing and commercialization efforts, market acceptance, market size and growth potential, and the ability to obtain and maintain intellectual property protection.
MAIA Biotechnology, Inc. filed a current report describing new investor presentation materials that its management plans to use from time to time, including at the Biotech Showcase conference in San Francisco, California on January 13, 2026. The presentation materials are included as Exhibit 99.1 and were also posted on the company’s website on January 13, 2026.
The company notes that the presentation materials contain forward-looking statements, emphasizing that readers and investors should be cautious in placing reliance on these statements. The filing is made as a Regulation FD disclosure and an “Other Events” update, with no separate financial results or major transactions described.
MAIA Biotechnology director Stan Smith reported indirect ownership changes in the company’s common stock. On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with him, purchased 2,700 shares of MAIA common stock at $3.6884 per share, bringing that trust’s reported indirect holdings to 1,424,178 shares.
On May 1, 2024, 20,000 shares previously held in the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, increasing that trust’s reported indirect holdings to 1,444,178 shares. Three additional IL Uniform Transfers to Minors Act accounts for family members each hold 4,580 shares, where Smith reports indirect beneficial ownership but disclaims it except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. reported that a company director received a new stock option grant. On 12/31/2025, the director was granted options to purchase 24,060 shares of MAIA Biotechnology common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of 12/31/2035. Following this grant, the director holds 24,060 derivative securities directly.
MAIA Biotechnology director option grant reported
MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The options cover 29,216 shares of common stock at an exercise price of $1.53 per share and vest 100% on the grant date, meaning they are exercisable beginning 12/31/2025.
The options have an expiration date of 12/31/2035. Following this grant, 29,216 derivative securities are shown as beneficially owned indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director reports new stock option grant
A MAIA Biotechnology, Inc. director filed a Form 4 disclosing a grant of stock options on December 31, 2025 under the company’s 2021 Equity Incentive Plan. The grant covers 25,206 stock options, each giving the right to buy one share of MAIA common stock at an exercise price of $1.53 per share. These options vest 100% on the grant date and are exercisable beginning that same day, with an expiration date of December 31, 2035. Following this grant, the reporting person holds 25,206 derivative securities directly, all in the form of these options.